JACC 82(9):833955 Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR et al (2020) Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association
She has won Castle Conolly Top Doctor for several years in a row, among other prestigious awards
These medications work by mimicking the action of the naturally occurring GLP-1 hormone, which is released from the intestine in response to food intake
Methods: Patients enrolled in this study (198 subjects) were participants from the BRAVES cohort (n=119 subjects with MASH) and LIBRA cohort (n=79 subjects without MASH)
158 Pancreatic polypeptide is thought to be important in inducing satiety as pancreatic polypeptide plasma levels are nearly eliminated in obese children with Prader-Willi syndrome
GLP-1 agonist medications have been on the market since 2005 with the release of exenatide (Byetta, AstraZeneca)
